Now, Moderna Says Its Vaccine Is 94.5% Effective in Preventing COVID-19

Tuesday, 17 Nov, 2020

Moderna Inc's experimental vaccine is 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial, the company said on Monday, becoming the second US drugmaker to report results that far exceed expectations.

It follows the announcement by another company Pfizer last week that its Covid-19 vaccine is 90pc effective.

The White House wants the Food and Drug Administration to act swiftly on emergency-use requests from companies, so they can produce as many doses as possible in the coming months.

"We are working with optimism and enthusiasm as part of the COVID-19 vaccine rollout task force".

"Positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent Covid-19 disease, including severe disease", says Stephane Bancel, Moderna's CEO.


Wall Street's main indexes opened higher on Monday after Moderna Inc said its experimental vaccine was 94.5% effective in preventing COVID-19, boosting hopes of the economy emerging from a year of pandemic-induced downturn.

What about the Pfizer vaccine?

Moderna said earlier Monday that its vaccine appears to be 94.5% effective, according to preliminary data from the company's still ongoing study.

The federal government has ordered 76 million doses of Pfizer's vaccine candidate, as well as 20 million firm orders for the Moderna candidate, with an option for 36 million more.

The interim analysis included 95 participants with confirmed cases of Covid-19, of which 90 had received the placebo and five the active vaccine.

Two doses are required: Like the Pfizer vaccine, two doses will be required of Moderna's vaccine. Of the 95 cases in Moderna's trial, 11 were severe and all 11 occurred among volunteers who got the placebo.

"The maximum effectiveness of the vaccine was observed seven days after the second dose".

The company believes that the vaccine can be stored at standard refrigeration temperatures of between 2C and 8C for up to 30 days and that is can be stored at -20C for six months. The trial involved 30,000 people in the US.

The vaccine can then be stored safely in a normal refrigerator for at least five days after being thawed out, possibly even longer, but again, we don't know yet.

England's deputy chief medical officer, Professor Jonathan Van-Tam said the Moderna results were "brilliant news".

If the EU Commission signs a contract with Moderna, the 160 million doses would be distributed evenly among its member states based on population. If Moderna's vaccine gets the OK soon, it is expected to be more widely available to areas without super-cold storage capacity, compared with Pfizer's vaccine. A small fraction of people experiences some severe but short-lived side-effects such as fatigue, headaches, muscle pain, as well as pain and redness around the injection site.

Speaking on BBC "Breakfast", Hancock said Britain will be "ready from the first of December", but that more likely it will begin "rolling out before Christmas".

"The results of this trial are truly striking", said Dr.

Europe's health regulator said on Monday it had launched a real-time "rolling review" of Moderna's vaccine, following similar reviews of vaccines from Pfizer and AstraZeneca.

With the new data published this week, Moderna could be the second company to seek authorization in the United States, after Pfizer.